CA2101104A1 - Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumors - Google Patents
Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumorsInfo
- Publication number
- CA2101104A1 CA2101104A1 CA002101104A CA2101104A CA2101104A1 CA 2101104 A1 CA2101104 A1 CA 2101104A1 CA 002101104 A CA002101104 A CA 002101104A CA 2101104 A CA2101104 A CA 2101104A CA 2101104 A1 CA2101104 A1 CA 2101104A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- substituents
- halogen
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
Abstract
Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions. Formula I is as follows:
(see formula I) wherein R1 and R2 each independently represents chlorine, bromine, iodine, OSO2Me, or OSO2phenyl (wherein phenyl is optionally substituted with 1,2,3,4 or 5 substituents independently selected from C1-4alkyl, halogen, -CN or -NO2);
R1a and R2a each independently represents hydrogen, C1-4alkyl or C1-4haloalkyl;
R3 and R4 each independently represents hydrogen, C1-4 alkyl or C1-4 haloalkyl;
R5a, R5b, R5c and R5d each independently represents hydrogen, C1-4 alkyl optionally containing one double bond or one triple bond, C1-4 alkoxy, halogen, cyano, -NH2, -CONR7R8 (wherein R7 and R8 are as defined below), -NH(C1-4-alkyl), -N(C1-4-alkyl)2 and C2-5alkanoyl; or R5a and R5b together represent a) C4 alkylene optionally having one double bond;
b) C3 alkylene ;or c) -CH=CH-CH=CH-, -CH=CH-CH2- or -CH2-CH=CH- each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, halogen, cyano, nitro, C2-5alkanoyl and -CONR7R8 (wherein R7 and R8 are as defined below);
X represents O, NH or -CH2-;
Y represents O;
2 represents -V-W where V is -CH2-T- in which T is -CH2-, -O-, -S-, -(SO)- or -(SO2)- (provided that when V has sulphur or oxygen as its second atom, W is other than -COON) and said group V optionally further carrying one or two substituents Q1 and/or Q2 on carbon;
wherein Q1 and Q2 each independently represents C1-4 alkyl or halogen; or, when Q1 and Q2 are bonded to adjacent carbon atoms, Q1 and Q2 together may additionally represent a C3-C4alkylene radical optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of C1-4alkyl and halogen; and W represents (1) COON, (2) -(C=O)-O-R6 wherein R6 represents a C1-6alkyl, C3-6cycloalkyl or aryl (as defined in 3 below) group;
(3) -(C=O)-NR7R8 wherein R7 and R8 each independently represent hydrogen or a C1-6alkyl, C3-6cycloalkyl, aryl, heteroaryl linked to N
via carbon or C7-9aralkyl group wherein aryl is phenyl;
heteroaryl is a 5 or 6 membered ring containing 1 to 3 heteroatoms selected from the group consisting of nitrogen and sulphur;
the aryl moiety per se, the heteroaryl moiety and the aryl moiety of the aralkyl group may be substituted on carbon with 1-4 substituents selected from the group consisting of -COOH, -OH, -NH2, -CH2-NH2, -(CH2)1-4-COOH, tetrazol-5-yl and -SO3H and the alkyl moiety may optionally carry a methyl group;
(4) -SO2NHR9 wherein R9 is as defined for R7 but may additionally represent -CF3, -CH2CF3 or aryl as defined above;
(S) SO3R10 in which R10 represents H, C1-6alkyl or C3-6cycloalkyl, (6) PO3R10R10 (wherein the R10 radicals, which may be the same or different, are as herein defined) (7) a tetrazol-5-yl group;
(8) -CONH-SO2R11 in which R11 represents (a) C3-7cycloalkyl;
(b) C1-6-alkyl optionally substituted with substituents selected from the group consisting of aryl as defined below, C1-4-alkyl, CF3 or halogen; and (c) perfluoro-C1-6alkyl; wherein aryl is phenyl or phenyl having 1-5 substituents wherein the substituents are selected from the group consisting of halogen, -NO2, -CF3, C1-4alkyl, C1-4alkoxy, -NH2, -NHCOCH3, -CONH2, -OCH2COOH, -NH(C1-4-alkyl), -N(C1-4-alkyl)2, -NHCOOC1-4alkyl, -OH, -COOH, -CN and -COOC1-4alkyl; and (9)-M-Het wherein b represents S, SO or SO2 and Het represents a.5: or 6 membered heterocyclic aromatic ring linked to M via a carbon atom of the aromatic ring, said aromatic.ring containing 1, 2, 3 or 4-heteroatoms selected from the group consisting of O, N and S said aromatic ring optionally being substituted on carbon atoms of the ring with 1, 2, 3 or 4 substituents selected from the group consisting of -OH, -SH, -CN, -CF3, NH2 and halogen.
(see formula I) wherein R1 and R2 each independently represents chlorine, bromine, iodine, OSO2Me, or OSO2phenyl (wherein phenyl is optionally substituted with 1,2,3,4 or 5 substituents independently selected from C1-4alkyl, halogen, -CN or -NO2);
R1a and R2a each independently represents hydrogen, C1-4alkyl or C1-4haloalkyl;
R3 and R4 each independently represents hydrogen, C1-4 alkyl or C1-4 haloalkyl;
R5a, R5b, R5c and R5d each independently represents hydrogen, C1-4 alkyl optionally containing one double bond or one triple bond, C1-4 alkoxy, halogen, cyano, -NH2, -CONR7R8 (wherein R7 and R8 are as defined below), -NH(C1-4-alkyl), -N(C1-4-alkyl)2 and C2-5alkanoyl; or R5a and R5b together represent a) C4 alkylene optionally having one double bond;
b) C3 alkylene ;or c) -CH=CH-CH=CH-, -CH=CH-CH2- or -CH2-CH=CH- each optionally substituted with 1, 2, 3 or 4 substituents said substituents each independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, halogen, cyano, nitro, C2-5alkanoyl and -CONR7R8 (wherein R7 and R8 are as defined below);
X represents O, NH or -CH2-;
Y represents O;
2 represents -V-W where V is -CH2-T- in which T is -CH2-, -O-, -S-, -(SO)- or -(SO2)- (provided that when V has sulphur or oxygen as its second atom, W is other than -COON) and said group V optionally further carrying one or two substituents Q1 and/or Q2 on carbon;
wherein Q1 and Q2 each independently represents C1-4 alkyl or halogen; or, when Q1 and Q2 are bonded to adjacent carbon atoms, Q1 and Q2 together may additionally represent a C3-C4alkylene radical optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of C1-4alkyl and halogen; and W represents (1) COON, (2) -(C=O)-O-R6 wherein R6 represents a C1-6alkyl, C3-6cycloalkyl or aryl (as defined in 3 below) group;
(3) -(C=O)-NR7R8 wherein R7 and R8 each independently represent hydrogen or a C1-6alkyl, C3-6cycloalkyl, aryl, heteroaryl linked to N
via carbon or C7-9aralkyl group wherein aryl is phenyl;
heteroaryl is a 5 or 6 membered ring containing 1 to 3 heteroatoms selected from the group consisting of nitrogen and sulphur;
the aryl moiety per se, the heteroaryl moiety and the aryl moiety of the aralkyl group may be substituted on carbon with 1-4 substituents selected from the group consisting of -COOH, -OH, -NH2, -CH2-NH2, -(CH2)1-4-COOH, tetrazol-5-yl and -SO3H and the alkyl moiety may optionally carry a methyl group;
(4) -SO2NHR9 wherein R9 is as defined for R7 but may additionally represent -CF3, -CH2CF3 or aryl as defined above;
(S) SO3R10 in which R10 represents H, C1-6alkyl or C3-6cycloalkyl, (6) PO3R10R10 (wherein the R10 radicals, which may be the same or different, are as herein defined) (7) a tetrazol-5-yl group;
(8) -CONH-SO2R11 in which R11 represents (a) C3-7cycloalkyl;
(b) C1-6-alkyl optionally substituted with substituents selected from the group consisting of aryl as defined below, C1-4-alkyl, CF3 or halogen; and (c) perfluoro-C1-6alkyl; wherein aryl is phenyl or phenyl having 1-5 substituents wherein the substituents are selected from the group consisting of halogen, -NO2, -CF3, C1-4alkyl, C1-4alkoxy, -NH2, -NHCOCH3, -CONH2, -OCH2COOH, -NH(C1-4-alkyl), -N(C1-4-alkyl)2, -NHCOOC1-4alkyl, -OH, -COOH, -CN and -COOC1-4alkyl; and (9)-M-Het wherein b represents S, SO or SO2 and Het represents a.5: or 6 membered heterocyclic aromatic ring linked to M via a carbon atom of the aromatic ring, said aromatic.ring containing 1, 2, 3 or 4-heteroatoms selected from the group consisting of O, N and S said aromatic ring optionally being substituted on carbon atoms of the ring with 1, 2, 3 or 4 substituents selected from the group consisting of -OH, -SH, -CN, -CF3, NH2 and halogen.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929215636A GB9215636D0 (en) | 1992-07-23 | 1992-07-23 | Chemical compounds |
| GB9215636.3 | 1992-07-23 | ||
| GB939310884A GB9310884D0 (en) | 1993-05-26 | 1993-05-26 | Chemical compounds |
| GB9310884.3 | 1993-05-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2101104A1 true CA2101104A1 (en) | 1994-01-24 |
| CA2101104C CA2101104C (en) | 2007-01-23 |
Family
ID=26301303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002101104A Expired - Fee Related CA2101104C (en) | 1992-07-23 | 1993-07-22 | Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumors |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US5405990A (en) |
| EP (1) | EP0651740B1 (en) |
| JP (1) | JP3541037B2 (en) |
| KR (1) | KR100268654B1 (en) |
| AT (1) | ATE172450T1 (en) |
| AU (1) | AU681349B2 (en) |
| CA (1) | CA2101104C (en) |
| CZ (1) | CZ287028B6 (en) |
| DE (1) | DE69321729T2 (en) |
| DK (1) | DK0651740T3 (en) |
| ES (1) | ES2123662T3 (en) |
| FI (1) | FI115048B (en) |
| GB (1) | GB9314960D0 (en) |
| HK (1) | HK1002683A1 (en) |
| HU (1) | HUT69288A (en) |
| IL (1) | IL106459A (en) |
| MY (1) | MY111635A (en) |
| NZ (1) | NZ254864A (en) |
| PH (1) | PH30004A (en) |
| PL (1) | PL174617B1 (en) |
| RU (1) | RU2129542C1 (en) |
| SK (1) | SK281338B6 (en) |
| TW (1) | TW272971B (en) |
| WO (1) | WO1994002450A1 (en) |
| ZW (1) | ZW9293A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| EP0708660B1 (en) * | 1993-07-15 | 2007-05-09 | Cancer Research Campaign Technology Limited | Compounds useful for preparing prodrugs of protein tyrosine kinase inhibitors |
| GB9315494D0 (en) * | 1993-07-27 | 1993-09-08 | Springer Caroline | Improvements relating to prodrugs |
| GB9415167D0 (en) * | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| GB9426133D0 (en) * | 1994-12-23 | 1995-02-22 | Zeneca Ltd | Chemical compounds |
| GB9501052D0 (en) * | 1995-01-19 | 1995-03-08 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| GB9510830D0 (en) * | 1995-05-27 | 1995-07-19 | Zeneca Ltd | Proteins |
| GB9517001D0 (en) * | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
| GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| WO1997034634A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US6395299B1 (en) | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| GB9907414D0 (en) | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| US6765019B1 (en) * | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| GB0001653D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Uk Ltd | Chemical compound |
| US8101200B2 (en) | 2000-04-13 | 2012-01-24 | Angiotech Biocoatings, Inc. | Targeted therapeutic agent release devices and methods of making and using the same |
| US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
| AU7570201A (en) * | 2000-07-26 | 2002-02-05 | Riley Patrick Anthony | Phenylethylamine derivatives and their use in the treatment of melanoma |
| GB0102239D0 (en) | 2001-01-29 | 2001-03-14 | Cancer Res Ventures Ltd | Methods of chemical synthisis |
| EP1434778A4 (en) | 2001-05-31 | 2005-07-13 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| EP1458728A1 (en) * | 2001-12-13 | 2004-09-22 | Ranbaxy Laboratories Limited | Crystalline cefdinir potassium dihydrate |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1537146B9 (en) | 2002-07-15 | 2011-07-06 | Board Of Regents, The University Of Texas System | Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections |
| US20040092735A1 (en) * | 2002-11-08 | 2004-05-13 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of cefuroxime sodium |
| WO2005000795A2 (en) * | 2003-06-10 | 2005-01-06 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
| RU2402548C2 (en) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Chemical linkers and conjugates thereof |
| WO2005112919A2 (en) * | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| CN101312748A (en) * | 2005-09-26 | 2008-11-26 | 梅达莱克斯公司 | Antibody-drug conjugates and methods of use |
| PL1940789T3 (en) | 2005-10-26 | 2012-04-30 | Squibb & Sons Llc | Methods and compounds for preparing cc-1065 analogs |
| WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| BRPI0717902A2 (en) | 2006-12-01 | 2013-10-29 | Medarex Inc | "HUMAN MONOCLONAL ANTIBODY ISOLATED, COMPOSITION, ASSOCIATED ANTIBODY-MOLLECLE PARTNERSHIP, IMMUNOCOUGHTED, ISOLATED NUCLEIC ACID MOLECULES, EXPRESSION VECTOR, HOSPEDIC CELL FOR PREPARING A CDT FOR THE PREPARATION OF A CD22 AND METHOD FOR TREATING INFLAMMATORY DISEASE OR SELF-IMMUNEING AN INDIVIDUAL " |
| CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
| NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
| TWI412367B (en) | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
| CL2008000510A1 (en) | 2007-02-21 | 2008-08-22 | Medarex Inc | FARMACO-LIGANDOS CONJUGATED COMPOUNDS, THAT JOIN POWERFUL CITOTOXINS; PHARMACEUTICAL COMPOSITION; AND USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER. |
| MX2010005104A (en) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Anti-vegf antibody compositions and methods. |
| ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
| EP3122757B1 (en) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| KR20220147721A (en) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| US11306055B2 (en) | 2017-05-15 | 2022-04-19 | Asahi Kasei Kabushiki Kaisha | Isocyanate production method |
| CN113845448B (en) * | 2021-10-20 | 2023-07-07 | 厦门大学 | Radioactivity (P) 18 F-labelled compounds and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| GB8820850D0 (en) * | 1988-09-05 | 1988-10-05 | Cancer Res Campaign Tech | Improvements relating to pro-drugs |
| GB8920011D0 (en) * | 1989-09-05 | 1989-10-18 | Mann J | New route of synthesis for tertiary butyl esters |
| WO1993008288A1 (en) * | 1991-10-23 | 1993-04-29 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form |
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
-
1993
- 1993-07-21 GB GB939314960A patent/GB9314960D0/en active Pending
- 1993-07-22 CA CA002101104A patent/CA2101104C/en not_active Expired - Fee Related
- 1993-07-22 IL IL106459A patent/IL106459A/en not_active IP Right Cessation
- 1993-07-22 US US08/094,952 patent/US5405990A/en not_active Expired - Lifetime
- 1993-07-23 ZW ZW9293A patent/ZW9293A1/en unknown
- 1993-07-23 EP EP93917904A patent/EP0651740B1/en not_active Expired - Lifetime
- 1993-07-23 DK DK93917904T patent/DK0651740T3/en active
- 1993-07-23 PL PL93307226A patent/PL174617B1/en not_active IP Right Cessation
- 1993-07-23 AU AU47156/93A patent/AU681349B2/en not_active Ceased
- 1993-07-23 AT AT93917904T patent/ATE172450T1/en not_active IP Right Cessation
- 1993-07-23 CZ CZ1995151A patent/CZ287028B6/en not_active IP Right Cessation
- 1993-07-23 JP JP50430994A patent/JP3541037B2/en not_active Expired - Lifetime
- 1993-07-23 DE DE69321729T patent/DE69321729T2/en not_active Expired - Fee Related
- 1993-07-23 HU HU9500145A patent/HUT69288A/en unknown
- 1993-07-23 ES ES93917904T patent/ES2123662T3/en not_active Expired - Lifetime
- 1993-07-23 SK SK69-95A patent/SK281338B6/en unknown
- 1993-07-23 KR KR1019950700225A patent/KR100268654B1/en not_active IP Right Cessation
- 1993-07-23 NZ NZ254864A patent/NZ254864A/en unknown
- 1993-07-23 RU RU95105246A patent/RU2129542C1/en not_active IP Right Cessation
- 1993-07-23 MY MYPI93001454A patent/MY111635A/en unknown
- 1993-07-23 PH PH6570A patent/PH30004A/en unknown
- 1993-07-23 WO PCT/GB1993/001560 patent/WO1994002450A1/en active IP Right Grant
- 1993-07-27 TW TW082106015A patent/TW272971B/zh active
-
1994
- 1994-12-21 US US08/361,424 patent/US5587161A/en not_active Expired - Lifetime
-
1995
- 1995-01-19 FI FI950230A patent/FI115048B/en not_active IP Right Cessation
- 1995-05-16 US US08/442,348 patent/US5660829A/en not_active Expired - Lifetime
-
1996
- 1996-09-30 US US08/722,669 patent/US5714148A/en not_active Expired - Lifetime
-
1997
- 1997-10-22 US US08/956,008 patent/US5958971A/en not_active Expired - Lifetime
-
1998
- 1998-02-27 HK HK98101571A patent/HK1002683A1/en not_active IP Right Cessation
-
1999
- 1999-05-19 US US09/314,894 patent/US6277880B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2101104A1 (en) | Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumors | |
| NO20013369L (en) | Arylpiperazinyl-cyclohexyl-indole derivatives for the treatment of depression | |
| HRP20010200B1 (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
| AU2910600A (en) | Phenyl urea and phenyl thiourea derivatives | |
| HUP0202186A2 (en) | Benzimidazolone derivatives, process for their preparation, pharmaceutical compositions containing them and their use as phosphodiesterase inhibitors for producing pharmaceutical compositions | |
| DE69418704D1 (en) | ANTHRANILE ACID DERIVATIVES | |
| MX9202142A (en) | NEW DERIVATIVES OF UREA, PROCESS FOR ITS PREPARATION, AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM. | |
| CO5080729A1 (en) | BENZIMIDAZOLES, ITS PREPARATION AND DRUGS THAT CONTAIN THEM | |
| ATE251613T1 (en) | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROS | |
| NO20013379L (en) | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| HK1048465A1 (en) | Aminobenzophenones as inhibitors of il-1B and tnf-a. | |
| DE69835430D1 (en) | Sulphonamide derivatives, their preparation and their use | |
| CA2359646A1 (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method | |
| AR029301A1 (en) | COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS | |
| HUP9802865A2 (en) | N-(substituted phenyl)-pyrazole-derivatives, preparation and use thereof, parasiticidal compositions containing these compounds as active ingredients | |
| TR200001010T2 (en) | Isoquinolins with urokinase inhibitors. | |
| WO2004054986A8 (en) | Process for the preparation of pyrimidine compounds | |
| ES2010284A6 (en) | Thiourea derivatives | |
| EP1144393A3 (en) | Heterocyclic derivatives and their use as integrin inhibitor | |
| CA2149239A1 (en) | Herbicidal sulfonylureas, their preparation and use | |
| YU58301A (en) | 2-aminopyridines containing fused ring substituents | |
| DE3769333D1 (en) | ACYLAMINOMETHYLIMIDAZO (1,2-A) PYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE. | |
| PT1068200E (en) | ANTIFUNGIC 1,3-DIOXOLANE 2,4,4-TIR-SUBSTITUTED | |
| HUT40620A (en) | Process for producing benzoyl-urea derivatives; and herbicide derivatives containing them as active agents | |
| ES2154551B1 (en) | NEW DERIVATIVES OF TETRAZOL AS ANTIDIABETIC AGENTS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |